By Life Sciences Report : Aging baby boomers face increased cancer risk, and growing numbers of obese and overweight Americans face metabolic disorders that could lead to cardiovascular disease. Debjit Chattopadhyay of ROTH Capital Partners recommends that biotech investors consider these trends ...
By Pannobhaso : [Originally published on 6/16/2014] Alnylam and Benitec Alnylam (NASDAQ: ALNY ) is a $5.1B company and Benitec Biopharma ( OTCPK:BTEBY ) ( OTCPK:BNIKF ) is a $120M company. Both are biothech companies
By Bio Terp : On July 3, 2014 , Tekmira (NASDAQ: TKMR ), "announced that the company has received verbal notice from the US FDA that the TKM-Ebola phase I healthy volunteer clinical study has been placed on clinical hold." Tekmira was in the process of conducting a phase I trial studying the ...
The USPTO issues a notice of allowance to Alnylam's (NASDAQ: ALNY ) patent application 13/693,478. The allowed patent broadly covers single- or double-stranded chemically modified RNA therapeutics
of options issued as a percentage of shares outstanding, putting shareholders at risk for future dilution. Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class
Foundation philanthropy subsidiary The Alpha-1 Project (TAP) enters into a collaboration agreement with Alnylam Pharmaceuticals ( ALNY -0.5% ) for the continued advancement of RNAi therapeutic ALN-AAT for the treatment of alpha-1 antitrypsin
We're maintaining our $66 fair value estimate for Alnylam Pharmaceuticals after first-quarter results that were consistent with our expectations. While Alnylam continued to advance its broad RNAi pipeline
Orders are in for the following; PRAN ARWR RLYP ALNY I have done some work looking at the newest holdings in both BIPIX and FBIOX, both great BIO TECH funds. My orders are based
We're maintaining our $42 fair value estimate for Alnylam Pharmaceuticals following third-quarter results that were in line with our expectations. Early in the third quarter, positive data for ALN
We're raising our fair value estimate for Alnylam ALNY to $42 per share from $31, as positive data for ALN-TTRsc came close on the heels of positive data for ALN-TTR02 earlier